Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin ® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Conditions:   Growth Hormone Deficiency in Children;   Born Small for Gestational Age Intervention:   Drug: Norditropin® FlexPro® Sponsor:   Novo Nordisk A/S Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

Bull Cancer. 2021 Sep 21:S0007-4551(21)00305-2. doi: 10.1016/j.bulcan.2021.05.011. Online ahead of print.ABSTRACTINTRODUCTION: In 2011, 11% of all cancers were diagnosed in people over 85 years old. With the current aging of the French population associated with health progress, we will be confronted more and more frequently with the treatment of very old patients, and this until the horizon 2050, when the population over 75 years old will represent approximately 15% of the total French population (compared to 9.1% in 2015).METHODS: To understand the management methods for patients over 85 years old with cancer, we carried...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Clin Endocrinol Metab. 2021 Sep 24:dgab699. doi: 10.1210/clinem/dgab699. Online ahead of print.NO ABSTRACTPMID:34558616 | DOI:10.1210/clinem/dgab699
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research
CONCLUSIONS.—: Publication in this area has markedly increased in the last 2 decades. However, most of the studies identified were descriptive and case reports describing changes seen in specimens removed as a part of masculinizing surgical procedures. Benign histologic findings include stromal hyalinization and epithelial atrophy in the breast, polycystic ovarian syndrome-like changes in the ovary, and transitional cell metaplasia in the cervix. The most commonly reported neoplastic finding was adenocarcinoma of the breast, with rare cases of ovarian, endometrial, cervical, vaginal, pituitary, pancreatic, and cardio...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Source Type: research
Ann Surg Oncol. 2021 Sep 23. doi: 10.1245/s10434-021-10807-3. Online ahead of print.ABSTRACTBACKGROUND: In most women ≥ 70 years old with hormone-receptor-positive breast cancer, axillary staging and adjuvant radiotherapy provide no survival advantage over surgery and hormone therapy alone. Despite recommendations for their omission, sentinel lymph node biopsy (SLNB) and adjuvant radiotherapy rates remain high. While treatment side effects are well documented, less is known about the incremental spending associated with SLNB and adjuvant radiotherapy.METHODS: Using a statewide multipayer claims registry, we examined spe...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists ’ underestimation of their symptoms and spiritual aspects. This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Her care team recommended hormone thera...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Izak Faiena The use of immunotherapy has become a critical treatment modality in many advanced cancers. However, immunotherapy in prostate cancer has not been met with similar success. Multiple interrelated mechanisms, such as low tumor mutational burden, immunosuppressive cells, and impaired cellular immunity, appear to subvert the immune system, creating an immunosuppressive tumor microenvironment and leading to lower treatment efficacy in advanced prostate cancer. The lethality of metastatic castrate-resistant prostate cancer is driven by the lack of therapeutic regimens capable of generating durable responses. Mult...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
J Clin Ethics. 2021 Fall;32(3):206-214.ABSTRACTIn this article, we analyze the ethics of elective growth hormone (GH) therapy in children with idiopathic short stature (ISS). We discuss recent clinical research regarding the efficacy, side-effects, and risks of GH therapy, and argue that GH therapy is ethically unjustifiable for most children with ISS.PMID:34548429
Source: Journal of Clinical Ethics - Category: Medical Ethics Authors: Source Type: research
Condition:   Menopause Interventions:   Drug: Hormone replacement therapy;   Drug: Selective serotonin reuptake inhibitors Sponsor:   Faculdade de Medicina do ABC Recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSION: In DCIS patients, the rate of second breast cancers was 7.5%. Breast conservation, involved margins after lumpectomy and shortened hormonal therapy were associated with second cancers. Patients with involved margins after lumpectomy have the highest cancer detection rate and minimal unnecessary biopsies and follow-ups. Hence, ipsilateral breast ultrasound surveillance could be personalized for this high-risk group with mammographically dense breasts.PMID:34544658 | DOI:10.1016/j.clbc.2021.08.006
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Around 10,000 men a year in the UK have an aggressive form of prostate cancer, which is treated with hormone therapy and radiotherapy. A new drug could halve death rates over six years.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Children | Hormonal Therapy | Hormones | Research